<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN" "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article article-type="editorial" dtd-version="1.4" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">odmj</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">OncoDaily Medical Journal</journal-title>
        <abbrev-journal-title abbrev-type="publisher">ODMJ</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">3067-6444</issn>
      <publisher>
        <publisher-name>OncoDaily Medical Journal</publisher-name>
        <publisher-loc>
          <country>US</country>
        </publisher-loc>
      </publisher>
      <self-uri xlink:href="https://oncodailyjournal.com/"/>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">142</article-id>
      <article-id pub-id-type="doi">10.69690/ODMJ-003-0924-142</article-id>
      <article-categories>
        <subj-group xml:lang="en" subj-group-type="heading">
          <subject>Editorials</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">New Leukaemia Drugs</article-title>
      </title-group>
      <contrib-group content-type="author">
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9156-1676</contrib-id>
          <name name-style="western">
            <surname>Gale</surname>
            <given-names>Robert Peter</given-names>
          </name>
          <aff xml:lang="en">Centre for Haematology, Department of Immunology and Inflammation Imperial College of Science, Technology and Medicine. London, UK SW7 2AZ, P – 1-908-656-0484, F – 1-310-388-1230</aff>
          <email>robertpetergale@alumni.ucla.edu</email>
          <bio xml:lang="en">
            <p>Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.</p>
          </bio>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="electronic">
        <day>01</day>
        <month>09</month>
        <year>2024</year>
      </pub-date>
      <elocation-id>ODMJ-003-0924-142</elocation-id>
      <permissions>
        <copyright-statement>Copyright (c) 2024 OncoDaily Medical Journal</copyright-statement>
        <copyright-year>2024</copyright-year>
        <copyright-holder>OncoDaily Medical Journal</copyright-holder>
      </permissions>
      <self-uri xlink:href="https://oncodailyjournal.com/10.69690/odmj-003-0924-142/"/>
      <kwd-group xml:lang="en">
        <kwd>Drugs</kwd>
        <kwd>Leukaemia</kwd>
        <kwd>Oncology</kwd>
        <kwd>Robert Peter Gale</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>production-ready-file-url</meta-name>
          <meta-value>
            <ext-link ext-link-type="uri" xlink:href="https://oncodailyjournal.com/pub/uploads/2024/09/Article-1.pdf"/>
          </meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body/>
  <back>
    <ref-list>
    </ref-list>
  </back>
</article>
